A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211
A Phase 1, Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211
Sponsor: Theravance Biopharma
Listed as NCT01568411, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Theravance Biopharma, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Oct 2018 — Sep 2020 [monthly]
Completed PHASE1
-
Jun 2018 — Oct 2018 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Theravance Biopharma
For direct contact, visit the study record on ClinicalTrials.gov .